Literature DB >> 25225224

Managing drug interactions in HIV-infected adults with comorbid illness.

Christine A Hughes1, Alice Tseng2, Ryan Cooper2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25225224      PMCID： PMC4284166          DOI： 10.1503/cmaj.131626

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  49 in total

1.  Evaluation of HIV drug interaction web sites.

Authors:  Nancy L Sheehan; Deborah V Kelly; Alice L Tseng; Rolf P G van Heeswijk; Lizanne C Béïque; Christine A Hughes
Journal:  Ann Pharmacother       Date:  2003-11       Impact factor: 3.154

2.  Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.

Authors:  John G Evans-Jones; Lucy E Cottle; David J Back; Sara Gibbons; Nicholas J Beeching; Peter B Carey; Saye H Khoo
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

3.  Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers.

Authors:  Parul Patel; Ivy Song; Julie Borland; Apurva Patel; Yu Lou; Shuguang Chen; Toshihiro Wajima; Amanda Peppercorn; Sherene S Min; Stephen C Piscitelli
Journal:  J Antimicrob Chemother       Date:  2011-04-14       Impact factor: 5.790

Review 4.  A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Authors:  R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland
Journal:  Expert Rev Clin Pharmacol       Date:  2013-05       Impact factor: 5.045

5.  Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.

Authors:  G W Hogeland; S Swindells; J C McNabb; A D M Kashuba; G C Yee; C M Lindley
Journal:  Clin Pharmacol Ther       Date:  2007-01       Impact factor: 6.875

6.  Ritonavir's role in reducing fentanyl clearance and prolonging its half-life.

Authors:  K T Olkkola; V J Palkama; P J Neuvonen
Journal:  Anesthesiology       Date:  1999-09       Impact factor: 7.892

7.  Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.

Authors:  Xiaodong Wang; Marta Boffito; Jenny Zhang; Ellen Chung; Li Zhu; Yaoshi Wu; Kristine Patterson; Angela Kashuba; Pablo Tebas; Michael Child; Lisa Mahnke; Richard Bertz
Journal:  AIDS Patient Care STDS       Date:  2011-07-19       Impact factor: 5.078

8.  Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir.

Authors:  Tuija H Nieminen; Nora M Hagelberg; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Kari Laine; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2010-08-10       Impact factor: 2.953

9.  Possible antiretroviral therapy-warfarin drug interaction.

Authors:  Patricia Pecora Fulco; Michelle M Zingone; Robert T Higginson
Journal:  Pharmacotherapy       Date:  2008-07       Impact factor: 4.705

10.  Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity?

Authors:  Joseph L Goulet; Shawn L Fultz; David Rimland; Adeel Butt; Cynthia Gibert; Maria Rodriguez-Barradas; Kendall Bryant; Amy C Justice
Journal:  Clin Infect Dis       Date:  2007-12-15       Impact factor: 9.079
View more
  7 in total

1.  Older HIV-infected adults. Complex patients (III): Polypharmacy.

Authors:  Samuel F Freedman; Carrie Johnston; John J Faragon; Eugenia L Siegler; Tessa Del Carmen
Journal:  Eur Geriatr Med       Date:  2018-12-06       Impact factor: 1.710

Review 2.  Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week.

Authors:  Sonu Abraham; Anju Nohria; Tomas G Neilan; Aarti Asnani; Anu Mariam Saji; Jui Shah; Tara Lech; Jason Grossman; George M Abraham; Daniel P McQuillen; David T Martin; Paul E Sax; Sourbha S Dani; Sarju Ganatra
Journal:  J Am Coll Cardiol       Date:  2022-10-06       Impact factor: 27.203

Review 3.  CD8+ T-Cell Response to HIV Infection in the Era of Antiretroviral Therapy.

Authors:  Federico Perdomo-Celis; Natalia A Taborda; Maria T Rugeles
Journal:  Front Immunol       Date:  2019-08-09       Impact factor: 7.561

Review 4.  Drug-Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives.

Authors:  Nicolas Cottura; Hannah Kinvig; Sandra Grañana-Castillo; Adam Wood; Marco Siccardi
Journal:  J Clin Pharmacol       Date:  2022-02-08       Impact factor: 2.860

Review 5.  Polypharmacy in HIV: recent insights and future directions.

Authors:  E Jennifer Edelman; Christopher T Rentsch; Amy C Justice
Journal:  Curr Opin HIV AIDS       Date:  2020-03       Impact factor: 4.061

6.  HIV pharmaceutical care in primary healthcare: Improvement in CD4 count and reduction in drug-related problems.

Authors:  C G R C Molino; Renata Cavalcanti Carnevale; Aline Teotonio Rodrigues; Patricia Moriel; Priscila Gava Mazzola
Journal:  Saudi Pharm J       Date:  2016-11-15       Impact factor: 4.330

7.  Profile of drug-drug interactions and impact on the effectiveness of antiretroviral therapy among patients living with HIV followed at an Infectious Diseases Referral Center in Belo Horizonte, Brazil.

Authors:  Betânia Maira Pontelo; Dirceu Bartolomeu Greco; Nathalia Sernizon Guimarães; Nina Rotsen; Victor Alberto Rebelo Braga; Pedro Henrique Nogueira Pimentel; Hugo Barbosa; Taciane Miranda Barroso; Unaí Tupinambás
Journal:  Braz J Infect Dis       Date:  2020-04-29       Impact factor: 3.257
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.